Sihuan Competitors

Delisted . USA . 
Stock . Sihuan Pharmaceutical Holdings
SHPHFDelisted Stock  USD 0.1  0.00  0.00%   
Sihuan Pharmaceutical competes with Procaps Group, Phibro Animal, Shuttle Pharmaceuticals, Kala Pharmaceuticals, and Lifecore Biomedical; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. Analyzing Sihuan Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Sihuan Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Sihuan Pharmaceutical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.1010.17
Details
Intrinsic
Valuation
LowRealHigh
0.000.0810.15
Details
Naive
Forecast
LowNextHigh
00.110.17
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.050.070.1
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Sihuan Pharmaceutical. Your research has to be compared to or analyzed against Sihuan Pharmaceutical's peers to derive any actionable benefits. When done correctly, Sihuan Pharmaceutical's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Sihuan Pharmaceutical.

Sihuan Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sihuan Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Sihuan and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sihuan Pharmaceutical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
CNNA
+ 0.74
PROC
MNK
+ 0.74
EGRX
SHPH
+ 0.73
EGRX
MNK
+ 0.67
SHPH
ACOR
+ 0.45
SSIC
MNK
+ 0.4
PROC
  
High negative correlations   
MNK
- 0.82
PAHC
CNNA
- 0.74
SSIC
PROC
- 0.64
SSIC
SHPH
- 0.62
PAHC
EGRX
- 0.6
PAHC
KALA
- 0.58
PROC

Risk-Adjusted Indicators

There is a big difference between Sihuan Pink Sheet performing well and Sihuan Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sihuan Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Sihuan Pharmaceutical Competitive Analysis

The better you understand Sihuan Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sihuan Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sihuan Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SHPHF SSIC PROC PAHC EGRX CNNA SHPH ACOR KALA MNK
 0.00 
 0.1 
Sihuan
 1.22 
 12.96 
Silver
 27.75 
 1.51 
Procaps
 0.93 
 23.37 
Phibro
 1.02 
 1.99 
Eagle
 3.03 
 0 
Cann
 2.30 
 0.85 
Shuttle
 2.41 
 16.20 
Acorda
 3.16 
 6.86 
Kala
 4.17 
 0.46 
Mallinckrodt
Market Volatility
(90 Days Market Risk)
Out of control
Not too volatile
Abnormally volatile
Not too volatile
Extremely Dangerous
Out of control
Out of control
Very steady
Somewhat reliable
Very steady
Market Performance
(90 Days Performance)
Solid
Solid
Insignificant
OK
Very Weak
Insignificant
Very Weak
Very Weak
Modest
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Average
Low
Dangerous
Very High
Very High
Dangerous
High
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Hold
Hold
Not Available
Not Available
Not Available
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Buy
Not Rated
Strong Sell
Strong Sell
Not Rated
Sell
Not Rated
Current Ratio
2.43
111.63
1.54
2.97
1.78
20.16
0.03
1.71
2.54
2.98
Net Asset
14.5 B
88.58 M
460.19 M
982.18 M
406.16 M
N/A
5.95 M
117.75 M
55.95 M
6.01 B
Profit Margin
-0.0543
0.45
0.13
0.0166
0.0464
N/A
N/A
-2.15
N/A
-0.83
EBITDA
914.73 M
7.34 M
57.06 M
84.61 M
65.48 M
(275.98 K)
(5.89 M)
8.4 M
(36.08 M)
(723.5 M)
Operating Margin
-0.0029
0.67
0.11
0.0811
0.16
-21.26
N/A
0.039
N/A
-0.0147
Current Valuation
506.36 M
32.12 M
434.45 M
1.37 B
82.05 M
48
3.52 M
161.45 M
19.45 M
2.62 B
Price To Book
0.81
0.78
4.33
3.66
0.1
7.0E-4
4.16
0.0527
4.61
0.069
Retained Earnings
5.54 B
449.27 K
(391.51 M)
243.89 M
111.5 M
(4 M)
(15.49 M)
(1.19 B)
(629.41 M)
(588.2 M)
Current Asset
6.17 B
N/A
N/A
342.83 M
119.05 M
N/A
N/A
451.32 M
84.65 M
1.51 B
Five Year Return
N/A
N/A
N/A
1.85
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.8
0.28
0.17
0.51
0.52
1.21
0.74
1.46
-2.14
3.06
Number Of Employees
3.9 K
5
5.5 K
1.94 K
134
1
8
102
43
2.67 K
Shares Outstanding
9.33 B
6.21 M
112.82 M
20.34 M
12.96 M
4.44 K
3.66 M
1.24 M
4.61 M
13.29 M
Cash Flow From Operations
665.29 M
7.98 M
62.99 M
87.59 M
30.8 M
(244.54 K)
(5.58 M)
(13.98 M)
(27.93 M)
455.4 M
Annual Yield
0.0217
0.094
N/A
0.0205
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
844.75 M
3.01 M
285.94 M
525.46 M
62.47 M
N/A
1.09 M
190.9 M
36.32 M
3.07 B
Return On Equity
-0.0487
0.0641
0.37
0.0655
0.0488
-2.6
-1.86
-0.24
-2.48
-1.11
Z Score
0.6
N/A
N/A
N/A
N/A
-12.6
N/A
N/A
N/A
0.09
Return On Asset
-4.0E-4
0.0562
0.0628
0.0526
0.0663
-0.85
-0.62
-0.0577
-0.4
-0.0029
Book Value Per Share
0.78
13.56
0.39
6.38
19.25
0.001
2.02
-127.17
2.72
47.06
Number Of Shares Shorted
N/A
9.78 K
113.8 K
463.35 K
350.53 K
N/A
58.92 K
8.1 K
30.48 K
1.79 M
Current Liabilities
1.51 B
N/A
N/A
108.78 M
35.45 M
384 K
N/A
90.59 M
10.53 M
1.23 B
Total Asset
14.5 B
88.58 M
460.19 M
982.18 M
406.16 M
417 K
5.95 M
117.75 M
55.95 M
6.01 B
Debt To Equity
0.14
N/A
6.02
1.79
0.23
0.14
0.091
2.56
4.77
1.44
Last Dividend Paid
0.014
0.98
N/A
0.48
N/A
N/A
N/A
N/A
N/A
N/A
Short Ratio
N/A
4.63
1.65
2.58
3.91
N/A
0.25
1.84
1.91
0.19
Target Price
N/A
8.8
5.0
18.4
17.0
N/A
N/A
10.0
15.0
1.75
Shares Owned By Institutions
4.21
76.19
2.81
99.43
76.65
N/A
1.81
13.22
48.13
96.64
Market Capitalization
1.2 B
66.13 M
235.8 M
955.48 M
27.73 M
421
3.12 M
821.03 K
31.61 M
4.52 M
Price To Earning
8.75
N/A
N/A
11.39
40.52
N/A
N/A
0.95
-0.52
1.09
Price To Earnings To Growth
N/A
N/A
N/A
1.66
0.91
N/A
N/A
0.51
N/A
-0.01
Price To Sales
0.41
5.32
0.57
0.91
0.11
0.0306
N/A
0.007
1.16
0.0616
Net Income
416.51 M
7.34 M
52.2 M
2.42 M
(2.67 M)
(249.82 K)
(6.59 M)
(252.85 M)
(42.2 M)
(717.4 M)
Earnings Per Share
0.01
0.9
0.51
0.43
0.85
-0.001
-4.25
-203.57
-11.67
-0.78
Shares Owned By Insiders
55.02
0.43
83.02
0.57
12.02
9.5
27.8
0.69
5.14
10.09
Revenue
3.29 B
11.72 M
414.1 M
1.02 B
316.61 M
13.23 K
N/A
117.63 M
N/A
2.21 B
Working Capital
4.66 B
N/A
(70.93 M)
396.85 M
77.67 M
(384 K)
4.55 M
(152.98 M)
44.52 M
1.29 B
Cash And Equivalents
5.25 B
60.62 M
37.55 M
98.67 M
36.56 M
59.87 K
50.44 K
20.7 M
44.57 M
1.34 B
Cash Per Share
0.56
9.75
0.37
2.44
2.75
N/A
N/A
0.85
30.44
26.93
Gross Profit
2.45 B
5.38 M
191.31 M
298.24 M
221.67 M
16.71 K
N/A
82.43 M
1.33 M
610 M
Day Typical Price
0.095
13.06
1.67
23.39
2.11
0.0032
0.84
15.99
6.74
0.47
Accumulation Distribution
N/A
0.0219
0.25
0.0245
0.2
N/A
0.0698
0.0861
0.0873
0.1
Market Facilitation Index
N/A
0.29
0.49
0.58
0.47
N/A
0.06
1.43
0.61
0.05
Daily Balance Of Power
0.0
(0.55)
(1.18)
(0.38)
0.0426
(9,223,372,036,855)
(0.33)
(0.28)
0.3443
(0.40)
Period Momentum Indicator
N/A
(0.16)
(0.58)
(0.22)
0.02
(0.0001)
(0.02)
(0.40)
0.21
(0.02)
Rate Of Daily Change
1.0
0.99
0.72
0.99
1.01
0.97
0.98
0.98
1.03
0.96
Day Median Price
0.095
13.11
1.75
23.4
2.17
0.0032
0.83
15.89
6.69
0.48
Price Action Indicator
N/A
(0.22)
(0.52)
(0.14)
(0.16)
(0.00005)
0.01
0.11
0.28
(0.03)
Relative Strength Index
N/A
49.58
27.31
72.87
46.41
30.2
38.46
57.29
66.84
37.4
Coefficient Of Variation
812.4
952.24
2399.49
1054.75
(567.97)
5264.68
(877.28)
1032.27
1169.57
3635.17
Mean Deviation
1.38
1.09
8.14
1.81
3.94
7.0
5.08
5.6
2.45
16.59
Jensen Alpha
0.6453
0.1726
0.3453
0.0187
(1.22)
0.242
(0.84)
1.25
0.2205
1.8
Total Risk Alpha
(0.26)
(0.11)
(2.10)
(0.18)
(2.32)
(2.02)
(2.21)
(0.82)
(0.28)
(8.16)
Sortino Ratio
N/A
0.0198
0.0552
0.0425
N/A
0.0068
N/A
0.1651
0.0592
0.0963
Downside Variance
N/A
1.84
101.79
3.64
N/A
316.23
N/A
35.25
5.81
233.18
Standard Deviation
5.68
1.57
16.67
2.31
6.74
13.6
7.84
11.54
3.28
58.48
Kurtosis
66.0
3.42
16.85
0.5921
16.35
5.91
6.98
30.45
1.67
59.21
Potential Upside
N/A
2.89
26.19
3.87
9.24
20.0
10.08
14.01
6.54
12.5
Treynor Ratio
2.0
(1.09)
0.2574
0.1401
(7.80)
5.04
1.91
(1.00)
0.6921
(1.03)
Maximum Drawdown
N/A
7.09
111.85
9.05
53.71
89.44
50.96
95.04
17.14
504.19
Variance
32.28
2.45
277.9
5.32
45.47
184.89
61.41
133.16
10.75
3420.05
Market Risk Adjusted Performance
2.01
(1.08)
0.2674
0.1501
(7.79)
5.05
1.92
(0.99)
0.7021
(1.02)
Risk Adjusted Performance
0.1028
0.0854
0.0414
0.0792
(0.13)
0.024
(0.08)
0.0834
0.073
0.0309
Skewness
8.12
1.06
3.26
0.6153
(2.65)
0.5032
1.16
4.75
1.1
7.5
Semi Deviation
N/A
1.04
8.79
1.71
N/A
10.36
N/A
5.26
2.22
13.99
Information Ratio
0.0989
0.0171
0.0334
0.0352
(0.20)
0.0089
(0.13)
0.0849
0.0435
0.0252
Value At Risk
N/A
(1.82)
(13.75)
(2.46)
(8.24)
(24.00)
(10.70)
(9.57)
(3.86)
(30.95)
Expected Short fall
N/A
(1.35)
(13.47)
(2.08)
N/A
(15.65)
N/A
(6.81)
(3.27)
(33.75)
Downside Deviation
N/A
1.36
10.09
1.91
N/A
17.78
N/A
5.94
2.41
15.27
Semi Variance
N/A
1.08
77.27
2.93
N/A
107.26
N/A
27.67
4.93
195.81

Sihuan Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Sihuan Pharmaceutical Competition

Sihuan Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sihuan Pharmaceutical in relation to its competition. Sihuan Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Sihuan Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sihuan Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sihuan Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Sihuan Pharmaceutical position

In addition to having Sihuan Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cigarettes Thematic Idea Now

Cigarettes
Cigarettes Theme
Tobacco makers and distributors across globe. The Cigarettes theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cigarettes Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Sihuan Pink Sheet

If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stocks Directory
Find actively traded stocks across global markets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY